243 related articles for article (PubMed ID: 25081321)
21. Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells.
Leung E; Kim JE; Rewcastle GW; Finlay GJ; Baguley BC
Cancer Biol Ther; 2011 Jun; 11(11):938-46. PubMed ID: 21464613
[TBL] [Abstract][Full Text] [Related]
22. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
23. CD79B limits response of diffuse large B cell lymphoma to ibrutinib.
Kim JH; Kim WS; Ryu K; Kim SJ; Park C
Leuk Lymphoma; 2016; 57(6):1413-22. PubMed ID: 26699656
[TBL] [Abstract][Full Text] [Related]
24. Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia.
Gallagher EJ; Fierz Y; Vijayakumar A; Haddad N; Yakar S; LeRoith D
Oncogene; 2012 Jul; 31(27):3213-22. PubMed ID: 22037215
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.
Sagiv-Barfi I; Kohrt HE; Czerwinski DK; Ng PP; Chang BY; Levy R
Proc Natl Acad Sci U S A; 2015 Mar; 112(9):E966-72. PubMed ID: 25730880
[TBL] [Abstract][Full Text] [Related]
26. Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.
Wu H; Hu C; Wang A; Weisberg EL; Wang W; Chen C; Zhao Z; Yu K; Liu J; Wu J; Nonami A; Wang L; Wang B; Stone RM; Liu S; Griffin JD; Liu J; Liu Q
Leukemia; 2016 Mar; 30(3):754-7. PubMed ID: 26139428
[No Abstract] [Full Text] [Related]
27. MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.
Kanteti R; Dhanasingh I; Kawada I; Lennon FE; Arif Q; Bueno R; Hasina R; Husain AN; Vigneswaran W; Seiwert T; Kindler HL; Salgia R
PLoS One; 2014; 9(9):e105919. PubMed ID: 25221930
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
30. Relationships between signaling pathway usage and sensitivity to a pathway inhibitor: examination of trametinib responses in cultured breast cancer lines.
Leung EY; Kim JE; Askarian-Amiri M; Rewcastle GW; Finlay GJ; Baguley BC
PLoS One; 2014; 9(8):e105792. PubMed ID: 25170609
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
Gohr K; Hamacher A; Engelke LH; Kassack MU
BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
[TBL] [Abstract][Full Text] [Related]
32. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Rasp KH; Illing B; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 May; 12():46. PubMed ID: 23705826
[TBL] [Abstract][Full Text] [Related]
33. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
34. Dual Inhibition of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110
Alfaro J; Pérez de Arce F; Belmar S; Fuentealba G; Avila P; Ureta G; Flores C; Acuña C; Delgado L; Gaete D; Pujala B; Barde A; Nayak AK; Upendra TVR; Patel D; Chauhan S; Sharma VK; Kanno S; Almirez RG; Hung DT; Chakravarty S; Rai R; Bernales S; Quinn KP; Pham SM; McCullagh E
J Pharmacol Exp Ther; 2017 May; 361(2):312-321. PubMed ID: 28298527
[TBL] [Abstract][Full Text] [Related]
35. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
36. The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.
Ruella M; Kenderian SS; Shestova O; Fraietta JA; Qayyum S; Zhang Q; Maus MV; Liu X; Nunez-Cruz S; Klichinsky M; Kawalekar OU; Milone M; Lacey SF; Mato A; Schuster SJ; Kalos M; June CH; Gill S; Wasik MA
Clin Cancer Res; 2016 Jun; 22(11):2684-96. PubMed ID: 26819453
[TBL] [Abstract][Full Text] [Related]
37. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
38. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
39. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib.
Sun B; Shah B; Fiskus W; Qi J; Rajapakshe K; Coarfa C; Li L; Devaraj SG; Sharma S; Zhang L; Wang ML; Saenz DT; Krieger S; Bradner JE; Bhalla KN
Blood; 2015 Sep; 126(13):1565-74. PubMed ID: 26254443
[TBL] [Abstract][Full Text] [Related]
40. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F
Oncotarget; 2016 Sep; 7(36):58142-58147. PubMed ID: 27494885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
